Catalogo dei prodotti della ricerca

FAGGIANO, ANTONGIULIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.866
EU - Europa 2.711
AS - Asia 1.553
SA - Sud America 59
AF - Africa 36
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 3
Totale 11.232
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.720
IT - Italia 1.207
SG - Singapore 719
BE - Belgio 479
IN - India 356
SE - Svezia 269
CN - Cina 211
ID - Indonesia 162
CA - Canada 130
GB - Regno Unito 116
DE - Germania 105
IE - Irlanda 101
FI - Finlandia 69
RU - Federazione Russa 69
BG - Bulgaria 61
RO - Romania 53
UA - Ucraina 42
NL - Olanda 38
FR - Francia 33
AR - Argentina 29
CH - Svizzera 19
BR - Brasile 18
MX - Messico 16
PH - Filippine 14
TG - Togo 13
IR - Iran 11
JP - Giappone 11
VN - Vietnam 11
ES - Italia 10
HK - Hong Kong 10
KR - Corea 9
LT - Lituania 8
PL - Polonia 8
TR - Turchia 8
TW - Taiwan 7
CL - Cile 6
PT - Portogallo 6
ZA - Sudafrica 6
JO - Giordania 5
NG - Nigeria 5
PK - Pakistan 5
AU - Australia 4
AL - Albania 3
AT - Austria 3
CO - Colombia 3
CZ - Repubblica Ceca 3
DZ - Algeria 3
EE - Estonia 3
PE - Perù 3
SA - Arabia Saudita 3
CI - Costa d'Avorio 2
EG - Egitto 2
ET - Etiopia 2
EU - Europa 2
RS - Serbia 2
TH - Thailandia 2
UG - Uganda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
DK - Danimarca 1
HR - Croazia 1
IL - Israele 1
KH - Cambogia 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MY - Malesia 1
SC - Seychelles 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 11.232
Salva come PNG Salva come JPEG
Città #
Fairfield 1.220
Ashburn 534
Woodbridge 508
Singapore 493
Brussels 477
Seattle 475
Houston 432
Wilmington 409
Cambridge 394
Rome 374
Chandler 329
San Paolo di Civitate 261
Princeton 224
Santa Clara 219
Jakarta 152
Ann Arbor 150
Lawrence 143
Millbury 142
San Diego 97
Beijing 94
New York 86
Dublin 83
Ottawa 80
Boston 73
Sofia 61
Milan 60
Plano 59
Boardman 51
Andover 50
Helsinki 44
Toronto 41
Phoenix 38
Moscow 34
Norwalk 28
Dearborn 27
Pune 27
Wigan 27
Federal 26
Bremen 23
Southend 23
Florence 22
London 22
Falkenstein 18
Lappeenranta 17
Bologna 15
Naples 15
Paris 15
Lomé 13
Frankfurt am Main 11
Hanoi 11
Zurich 11
Dallas 10
Des Moines 10
Falls Church 10
Groningen 10
Guangzhou 10
Springfield 9
Bühl 8
Hefei 8
Latina 8
Los Angeles 8
Mannheim 8
Romainville 8
San Mateo 8
Turin 8
Wuhan 8
Buffalo 7
Cappelle sul Tavo 7
Nanjing 7
Nuremberg 7
Stockholm 7
Bari 6
Butuan 6
Hangzhou 6
Hyderabad 6
Livorno 6
Osaka 6
Pavia 6
Redwood City 6
Trumbull 6
Amman 5
Catania 5
Chennai 5
Edinburgh 5
Genoa 5
Lagos 5
Laurel 5
Montesilvano Marina 5
Nanchang 5
Redmond 5
Amsterdam 4
Hong Kong 4
Istanbul 4
Mexico City 4
Muizenberg 4
Mumbai 4
New Delhi 4
Padova 4
Palermo 4
Seodaemun-gu 4
Totale 8.548
Salva come PNG Salva come JPEG
Nome #
Angiogenic factors as prognostic markers in neuroendocrine neoplasms 176
Application of molecular biology of differentiated thyroid cancer for clinical prognostication 130
Capecitabine and Temozolomide (CAPTEM) in advanced neuroendocrine neoplasms (NENs): a systematic review and pooled analysis 118
Bone metabolism, bone mass and structural integrity profile in professional male football players 104
Combined biological therapy with lanreotide autogel and cabergoline in the treatment of MEN-1-related insulinomas 98
Ruolo diagnostico, prognostico e predittivo di risposta del NETest nelle neoplasie neuroendocrine 91
A Novel MAX Gene Mutation Variant in a Patient With Multiple and “Composite” Neuroendocrine–Neuroblastic Tumors 89
A decrease of calcitonin serum concentrations less than 50 percent 30 minutes after thyroid surgery suggests incomplete C-cell tumor tissue removal 86
Italian Society of Endocrinology Consensus Statement: Definition, evaluation and management of patients with mild primary hyperparathyroidism 83
Real-world study of everolimus in advanced progressive neuroendocrine tumors. 81
Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels 81
Accuracy of Fine Needle Cytology in Histological Prediction of Papillary Thyroid Carcinoma Variants: a Prospective Study 80
Efficacy and safety of radiofrequency thermal ablation in the treatment of thyroid nodules with pressure symptoms in elderly patients 79
Clinical and prognostic implications of the genetic diagnosis of hereditary NET syndromes in asymptomatic patients 79
Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients 79
Selenium supplementation in the management of thyroid autoimmunity during pregnancy: results of the "SERENA study", a randomized, double-blind, placebo-controlled trial 79
Quality of life in patients with neuroendocrine neoplasms. The role of severity, clinical heterogeneity and resilience 77
Diagnosis and Differential Diagnosis of Medullary Thyroid Cancer 76
Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors 76
Clinical presentation and management of patients with primary hyperparathyroidism in Italy 76
Animal models of medullary thyroid cancer: state of the art and view to the future 76
Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients 75
Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism 75
Hepatic arterial embolization in patients with neuroendocrine tumors 75
Limitations of Chromogranin A in clinical practice 74
Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastases 74
Thyroid nodules and related symptoms are stably controlled two years after radiofrequency thermal ablation 74
The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study 74
Predictors of malignancy in high-risk indeterminate (TIR3B) cytopathology thyroid nodules 74
Advances in the Management of Medullary Thyroid Carcinoma. Focus on Peptide Receptor Radionuclide Therapy 72
CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR 71
Rare diseases in clinical endocrinology: a taxonomic classification system 71
Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy 71
Hereditary neuroendocrine tumor syndromes 71
PRRT. identikit of the perfect patient 71
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues 70
Thyroid nodules treated with percutaneous radiofrequency thermal ablation: a comparative study 69
Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET 69
Functional characterization of human thyroid tissue with immunohistochemistry 69
Unintentional recurrent laryngeal nerve injuries following thyroidectomy. Is it the surgeon who pays the bill? 69
Heterogeneity of duodenal neuroendocrine tumors: an Italian multi-center experience 68
Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case–control study 68
Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database 67
Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib 66
Open issues on G3 neuroendocrine neoplasms: back to the future 66
Impact of nutritional status on gastroenteropancreatic neuroendocrine tumors (GEP-NET) aggressiveness 66
Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: a real-world study 65
Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib 65
The safety of available treatments options for neuroendocrine tumors 64
Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer 63
Diabetes and pancreatic neuroendocrine tumours: which interplays, if any? 63
Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours 63
Natural history of localized and locally advanced lung atypical carcinoid after complete resection: a joined french-italian multicentric retrospective study 63
A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors 63
Genetic-clinical profile of subjects with apparently sporadic extra-adrenal paragangliomas 62
Targeted therapy with kinase inhibitors in aggressive endocrine tumors 62
Epigenetics in medullary thyroid cancer: from pathogenesis to targeted therapy 62
The evolving field of kinase inhibitors in thyroid cancer 62
Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life 62
Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study 61
Cinacalcet in the management of primary hyperparathyroidism: post marketing experience of an Italian multicentre group 60
Efficacy and safety of everolimus in extrapancreatic neuroendocrine tumor: a comprehensive review of literature 60
Chromogranin a as circulating marker for diagnosis and management of neuroendocrine neoplasms: More flaws than fame 60
US-guided percutaneous radiofrequency thermal ablation for the treatment of solid benign hyperfunctioning or compressive thyroid nodules 60
GLP-1: benefits beyond pancreas 60
Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives 60
Multiple endocrine neoplasia type 1: analysis of germline MEN1 mutations in the Italian multicenter MEN1 patient database 60
Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study 60
Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study 60
Epidemiology of pancreatic neuroendocrine neoplasms. a gender perspective 60
Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma 59
Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms 59
Complete disappearance of liver metastases in a patient with iodine-refractory differentiated thyroid cancer subjected to sorafenib re-challenge 59
Natural History and Management of Familial Paraganglioma Syndrome Type 1: Long-Term Data from a Large Family 59
Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs. A Multicenter Study 59
Bone metastases in neuroendocrine neoplasms: from pathogenesis to clinical management 59
Immune Checkpoint Blockade in Lung Carcinoids with Aggressive Behaviour. One More Arrow in Our Quiver? 59
Correction to. Neuroendocrine neoplasms in the context of inherited tumor syndromes. a reappraisal focused on targeted therapies 58
Pituitary function and morphology in Fabry disease 58
Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group 58
Emerging therapies in pheochromocytoma and paraganglioma. immune checkpoint inhibitors in the starting blocks 58
Pathology reporting in neuroendocrine neoplasms of the digestive system: everything you always wanted to know but were too afraid to ask 58
Case Report. Unmasking Hypercalcemia in Patients With Neuroendocrine Neoplasms. Experience From Six Italian Referral Centers 57
Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1) 56
Screening of pancreaticoduodenal endocrine tumours in patients with MEN 1: multidetector-row computed tomography vs. endoscopic ultrasound 56
Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1) 55
Thyroid profile during the alternative Sunitinib dosing 2/1 schedule in metastatic renal cell carcinoma 55
Potential role of cinacalcet hydrochloride in sporadic primary hyperparathyroidism without surgery indication 54
Contrast enhanced multi-detector CT and MR findings of a well-differentiated pancreatic vipoma 54
Circulating tumor cells and miRNAs as prognostic markers in neuroendocrine neoplasms 54
Laryngeal neuroendocrine tumor with elevated serum calcitonin: a diagnostic and therapeutic challenge. Case report and review of literature 54
Erectile dysfunction and diabetes. A melting pot of circumstances and treatments 54
Commentary: case report: abdominal lymph node metastases of parathyroid carcinoma: diagnostic workup, molecular diagnosis, and clinical management 54
Management of adrenocortical carcinoma. a consensus statement of the Italian Society of Endocrinology (SIE) 53
Rapidly progressing high o,p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results 53
Spinal deformity index in patients with type 2 diabetes 53
Sunitinib treatment for advanced paraganglioma: case report of a novel SDHD gene mutation variant and systematic review of the literature 53
Diagnosis of Flier's syndrome in a patient with nondiabetic hypoglycemia. a case report and critical appraisal of the literature 53
Epidemiology of non-gastroenteropancreatic (neuro)endocrine tumours 52
The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery 52
Totale 6.838
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.052
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.052
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.552 0 0 0 0 0 0 324 324 321 274 103 206
2020/20211.066 121 177 73 33 71 72 51 76 149 94 100 49
2021/20222.117 39 85 191 92 243 45 66 228 205 82 485 356
2022/20232.205 407 486 80 186 163 142 31 119 318 52 150 71
2023/20241.735 95 208 74 144 155 287 68 81 24 171 213 215
2024/20252.067 91 192 758 394 282 334 16 0 0 0 0 0
Totale 12.395